BioFactura

Its biodefense programmes include a smallpox therapeutic and, in the past, work against Ebola. The smallpox programme is an antibody-based countermeasure intended to complement existing antivirals.

In September 2019 the US Department of Health and Human Services, through BARDA, awarded it contract 75A50119C00054 for preclinical, manufacturing and clinical development of the therapeutic, with a potential value of up to about 65.8 million dollars on the federal contract record and a performance place in Frederick. The same record shows the potential end date extended to March 2029 and a termination for convenience recorded in September 2025.

The company also develops biosimilars for autoimmune and infectious diseases and medicines for cancer. Its website describes more than 20 years of work taking drugs and vaccines from research to patients.

Privately held; ownership not publicly disclosed

Parent: none (publicly listed)

• https://www.biofactura.com/company/
• https://www.biofactura.com/pipeline/smallpox-therapeutic/
• https://www.highergov.com/contract/75A50119C00054/

• Ownership and investors: not disclosed in sources read.
• Reported contract ceilings differ between secondary sources (about 65.8 to 78 million dollars); the federal record value is used.
• Reason for and effect of the September 2025 termination on the smallpox programme: not stated.
• Whether the Phase 1 trial planned for 2025 started: not found.